Evogene (EVGN) Interest Expenses (2013 - 2026)
Evogene (EVGN) posted Interest Expenses of -$3.9 million for Q1 2026, down 1009.71% sequentially from -$350000.0 in Q4 2025, and down 748.03% YoY from $599350.4 in Q1 2025.
Evogene (EVGN) Interest Expenses (2013 - 2026) Analysis & Trends
Evogene has reported Interest Expenses for 14 years, with the latest figure at -$3.9 million in Q1 2026.
- Quarterly Interest Expenses fell 748.03% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.1 million (down 36.69% YoY) and the FY2025 annual result came in at -$1.9 million, down 157.56% from the prior year.
- Interest Expenses fell to -$3.9 million in Q1 2026 per EVGN's latest filing, from -$350000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.1 million in Q2 2025 and troughed at -$3.9 million in Q1 2026.
- A 5-year average of -$671588.2 and a median of -$255000.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses slumped 2558.02% in 2022, then jumped 399.08% in 2025.
- Over 5 years, Interest Expenses stood at $191000.0 in 2022, then tumbled by 137.17% to -$71000.0 in 2023, then plunged by 253.52% to -$251000.0 in 2024, then plunged by 39.44% to -$350000.0 in 2025, then slumped by 1009.71% to -$3.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$3.9 million, -$350000.0, and -$453000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -3.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.88 Mn |
| Mar 31, 2026 | -3.88 Mn |
| Dec 31, 2025 | -350,000.00 |
| Dec 31, 2025 | -350,000.00 |
| Sep 30, 2025 | -453,000.00 |
| Sep 30, 2025 | -453,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | -458,000.00 |
| Mar 31, 2025 | -458,000.00 |
| Dec 31, 2024 | -251,000.00 |
| Dec 31, 2024 | -251,000.00 |
| Sep 30, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -71,000.00 |
| Dec 31, 2023 | -71,000.00 |